Steroid Therapy in Severe Viral Hepatitis

Authors:
  • PGPeter B. Gregory
    Peter B. Gregory
  • CKC. Michael Knauer
    C. Michael Knauer
  • RKRichard L. Kempson
    Richard L. Kempson
  • RMRupert Miller
    Rupert Miller

Abstract
The efficacy of corticosteroid therapy in severe viral hepatitis has never been demonstrated in a controlled clinical trial. For this reason, patients with severe viral hepatitis were randomly assigned to methyl-prednisolone or placebo treatment groups. The two groups were comparable in clinical findings, laboratory results and the presence of bridging necrosis on liver biopsy. Seven of the 14 patients assigned to methyl-prednisolone and two of the 15 assigned to placebo died during the 16-week study period. Although the apparent excess mortality in the steroid-treated patients is not quite statistically significant (P = 0.08), the trend persists when only patients positive for hepatitis B surface antigen (P = 0.08) or those with bridging necrosis (P = 0.04) are analyzed separately.

This publication has 24 references indexed in Scilit: